Pieris

Contact
pieris.com
+4981611411400

Pieris AG

Lise-Meitner-Straße 30
85354 Freising
Germany
+4981611411400
pieris.com
Contact
Profile Products News
Contact

About Pieris

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

Read more about Pieris
Facts about Pieris
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Pieris

Product portfolio

Show all

News about Pieris

Pieris

19-May-2015 | people

Pieris Pharmaceuticals Appoints Jean-Pierre Bizzari, M.D., to its Board of Directors

Pieris Pharmaceuticals, Inc. announced that Jean-Pierre Bizzari, M.D. has joined the Company's Board bringing the total number of directors to six. Dr. ...

Read news
Pieris

01-Apr-2015 | business & finance

Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program

Pieris Pharmaceuticals, Inc. (OTCQB:PIRS) and The University of Melbourne announced the receipt by the University of a research grant to further develop ...

Read news
Pieris

15-Dec-2014 | research and development

Pieris Initiates Phase I Clinical Trial for Anticalin® to Treat Anemia

Pieris AG announced the initiation of a Phase I clinical trial with PRS-080, an anti-hepcidin Anticalin® therapeutic protein designed to treat anemia. The ...

Read news
Pieris

09-Feb-2012 | business & finance

Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program

Grant Supports Personalized Anti-cancer Approach on Path to Clinic

Read news
Pieris

25-Oct-2011 | business & finance

EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia

Consortium Will Receive Six Million Euro from Seventh Framework Programme

Read news
Pieris

25-May-2011 | research and development

Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin PRS-080 Hepcidin Antagonist Drug Program

Pieris AG announced preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a ...

Read news
Pieris

14-Apr-2011 | research and development

Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin Therapeutics

Pieris AG announced the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited under which Pieris will apply its ...

Read news
Pieris

30-Sep-2010 | business & finance

Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics

Pieris AG announced the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi ...

Read news
Show more news about Pieris

Here you will find Pieris AG